Meeting
2024 ASCO Genitourinary Cancers Symposium
Nonadherence to medications for chronic conditions and risk of nonadherence to androgen receptor signaling inhibitors (ARSIs) in patients with prostate cancer.
Authors
Morgan RL Lichtenstein
Beth Israel Deaconess Medical Center, Boston, MA
Morgan RL Lichtenstein , Alexander Z Wei , Boris Gershman , Mark N. Stein , Dawn L. Hershman , Rohit R. Raghunathan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 92)
DOI
10.1200/JCO.2024.42.4_suppl.92
Abstract #
92
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Somatostatin receptor 1 (SSTR1) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Xiaolin Zhu
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy.
First Author: Aishwarya Subramanian
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
First Author: Evan Y. Yu
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).
First Author: Benjamin H. Lowentritt